UnknownNot applicableNCT04590183
The Effectiveness and Safety of FK-506 for the Treatment of Posner-Schlossman Syndrome
Studying Glaucomatocyclitic crisis disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Peking University
- Principal Investigator
- Chun Zhang, PHD,MDPeking University Third Hospital
- Intervention
- FK-506 (Drug)(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2020 – 2021
Study locations (1)
- Peking University Third Hosipital, Beijing, Beijing Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04590183 on ClinicalTrials.gov